However, P2RY1 expression is significantly decreased by 3-fold in IPF tissue compared to normal (4.286 ± 0.277 vs. 14.431 ± 0.872), whereas there is significantly increased expression of ADORA1 (3-fold; 0.759 ± 0.066 vs. 0.257 ± 0.033), P2RY6 (2-fold; 1.967 ± 0.168 vs. 0.853 ± 0.125), P2RY10 (3-fold; 4.195 ± 0.362 vs. 1.286 ± 0.126), and P2RY11 (2-fold; 1.902 ± 0.150 vs. 1.027 ± 0.127) in IPF tissue compared to normal (p < 0.001), therefore suggesting that these could be potential therapeutic targets for IPF. This evidence concerns the gene P2RY1 and idiopathic pulmonary fibrosis.